Financial Analyst/Sr. Financial Analyst - Newark, CA | Biospace
Get Our FREE Industry eNewsletter

Financial Analyst/Sr. Financial Analyst

Depomed, Inc.

Newark, CA
Posted Date:
Position Type:
Full time
Job Code:
Required Education:
Bachelors Degree
Areas of Expertise Desired:

Job Description

City Newark
State California [CA]
Title Financial Analyst/Sr. Financial Analyst
Job ID 1019XX
Date Added 9/13/2017
Department Finance


The Financial Analyst/Sr. Financial Analyst position is a hands-on, revenue finance and accounting position at Depomed, working within a dynamic and energetic Financial Planning and Analysis (FP&A) team. The primary responsibility of the position is to handle Revenue Accounting, Analytics and the Gross-to-Net process for Depomed’s six products with the opportunity to work on the operational finance and accounting of the company. The position will report into the Senior Finance Manager.

•Responsible for revenue and gross-to-net accounting and analytics for 6 products
•Responsible for product sales discounts and rebate tracking and estimates for managed care contracts, Part D contracts, co-pay card programs, wholesaler fees, medicaid, government rebates and patient discount programs
•Responsible for product returns tracking and estimates
•Manage data for government pricing calculations
•Assist with the preparation and delivery of the quarterly returns reserve presentation to the management team
•Manage sales discount and rebate reimbursement and coordinate with external managed care rebate processor and review and investigate managed care invoice calculations
•Prepare and present monthly and quarterly revenue related reporting
•Assist with the external financial reporting process and prepare the revenue related disclosures for 10Q's and 10K
•Responsible for implementing and maintaining internal controls around the Revenue Recognition Process
•Assist in managing Third Party Logistics Company
•Assist in internal management financial reporting, including budget versus actual reporting, variance and trend analyses
•Assist in special projects and ad-hoc financial analyses
•Participate in the month-end close process, including reconciliations and preparation of financials
•Assist in revenue forecasting

•Develop strong cross-functional working relationships with Managed Markets and Trade department
•Interaction with executives


•Bachelor’s degree in Finance or Accounting
•2-3+ years of experience in Finance or Accounting. Revenue accounting experience is a plus but not required.
•Pharma/Biotech experience a plus

•Must have strong attention to detail and be well organized
•Must be a strong team player
•Strong Communication
•Competency with Excel
•Systems: Adaptive Insights and Microsoft A/X experience a plus

•Decisions & Judgment
•Ownership & Initiative
•Adaptability & Change Readiness
•Teamwork & Collaboration

•Sitting 80%
•Standing/ walking: 10%
•Repetitive motion: 50%
•Visual Requirements: 100%
About Us
Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. Founded in 1995, Depomed has successfully executed on strategy of acquiring, integrating and growing differentiated therapeutic products and building each into a strong market presence. The result is a broad portfolio of pain and neurology specialty pharmaceuticals currently comprised of five FDA-approved products. These include Gralise® for the management of Postherpetic Neuralgia (PHN), Cambia® for the acute treatment of migraine attacks, Zipsor® for the relief of mild to moderate acute pain, Lazanda® for the management of breakthrough pain in cancer patients and our most recent addition, the company’s flagship asset, the NUCYNTA® franchise.

Acquired in April 2015 and re-launched in June 2015, the NUCYNTA franchise includes NUCYNTA® ER for the extended management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) and NUCYNTA® for immediate management of moderate to severe acute pain in adults.

Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. The company’s Acuform technology is currently being used in four marketed drugs, including Gralise.

Depomed’s successful execution on strategy and has resulted in solid product revenue growth over the past three years. Located in Newark, California in the East Bay of San Francisco, Depomed is listed on the NASDAQ market under the ticker DEPO and employs approximately 500 people, of which approximately 350 are part of the Commercial organization.

Depomed is an AA/EEO/Veterans/Disabled employer.